Vistagen Therapeutics Inc. (NASDAQ:VTGN) finished Wednesday with a subtraction of -$0.39 to close at $7.03, a downside of -5.19 percent. An average of 14,653,240 shares of common stock have been traded in the last five days. There was a gain of $5.30 in the past week, and it reached a new high 12 times over the past 12 months. The last 20 days have seen an average of 3,746,915 shares traded, while the 50-day average volume stands at 1,719,824.
VTGN stock has increased by 313.82% in the last month. The company shares reached their 1-month lowest point of $1.63 on 08/04/23. With the stock rallying to its 52-week high on 08/07/23, shares of the company touched a low of $1.62 and a high of $24.71 in 52 weeks. It has reached a new high 13 times so far this year and achieved 127.67% or $3.94 in price. In spite of this, the price is down -71.53% from the 52-week high.
Valuation Metrics
Vistagen Therapeutics Inc. (VTGN) stock’s beta is 0.26. Other valuation ratios to consider include the price-to-book (PB) ratio at 4.04.
Financial Health
The quick ratio of Vistagen Therapeutics Inc. for the three months ended March 30 was 3.80, and the current ratio was 3.80, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.01 for the quarter ending March 30. Its gross profit as reported stood at $59.04 million compared to revenue of -$0.23 million.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Vistagen Therapeutics Inc.’s return on assets was -157.80%.
Earnings Surprise
In the quarter under review, the net income was down than the previous quarter. The company posted a net income of -$12.23 million in the quarter, while revenues of -$9.76 million were shrunk -36.47%. The analyst consensus anticipated Vistagen Therapeutics Inc.’s latest quarter earnings to come in at -$1.5 per share, but it turned out to be -$1.75, a -16.70% surprise. For the quarter, EBITDA amounted to -$12.21 million. Shareholders own equity worth $7.87 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Vistagen Therapeutics Inc. (VTGN) price momentum. RSI 9-day as of the close on 09 August was 61.94%, suggesting the stock is Neutral, with historical volatility in this time frame at 1,090.03%.
As of today, VTGN’s price is $6.18 +306.65% or $5.30 from its 5-day moving average. VTGN is currently trading +306.65% higher than its 20-day SMA and +60.07% higher than its 100-day SMA. However, the stock’s current price level is +78.06% above the SMA50 and +110.69% above the SMA200.
The stochastic %K and %D were 32.66% and 30.17%, respectively, and the average true range (ATR) was 2.86. With the 14-day stochastic at 23.42% and the average true range at 2.03, the RSI (14) stands at 62.42%. The stock has reached 4.94 on the 9-day MACD Oscillator while the 14-day reading was at 5.82.
Analyst Ratings
Maxim Group upgraded Vistagen Therapeutics Inc. (NASDAQ: VTGN) to a a Buy rating in its most recent analyst report. Previously, the stock was rated as a Hold. The consensus rating for Vistagen Therapeutics Inc. (VTGN) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell VTGN, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 1 others rate it as a “buy”.
What is VTGN’s price target for the next 12 months?
Analysts predict a range of price targets between $30.00 and $30.00, with a median target of $30.00. Taking a look at these predictions, the average price target given by analysts for Vistagen Therapeutics Inc. (VTGN) stock is $30.00.
